Cerebrospinal Fluid and Plasma Biomarkers in Alzheimer Disease

Overview

Journal Nat Rev Neurol

Specialty Neurology

Date 2010 Feb 17

PMID 20157306

Citations 779

Authors

Kaj Blennow

Harald Hampel

Michael Weiner

Henrik Zetterberg

Affiliations

Soon will be listed here.

Abstract

Intense multidisciplinary research has provided detailed knowledge of the molecular pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new therapeutic strategies with putative disease-modifying effects. Several of the most promising approaches, such as amyloid-beta immunotherapy and secretase inhibition, are now being tested in clinical trials. Disease-modifying treatments might be at their most effective when initiated very early in the course of AD, before amyloid plaques and neurodegeneration become too widespread. Thus, biomarkers are needed that can detect AD in the predementia phase or, ideally, in presymptomatic individuals. In this Review, we present the rationales behind and the diagnostic performances of the core cerebrospinal fluid (CSF) biomarkers for AD, namely total tau, phosphorylated tau and the 42 amino acid form of amyloid-beta. These biomarkers reflect AD pathology, and are candidate markers for predicting future cognitive decline in healthy individuals and the progression to dementia in patients who are cognitively impaired. We also discuss emerging plasma and CSF biomarkers, and explore new proteomics-based strategies for identifying additional CSF markers. Furthermore, we outline the roles of CSF biomarkers in drug discovery and clinical trials, and provide perspectives on AD biomarker discovery and the validation of such markers for use in the clinic.

Citing Articles

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.

Thal D, Poesen K, Vandenberghe R, De Meyer S Mol Neurodegener. 2025; 20(1):33.

PMID: 40087672 DOI: 10.1186/s13024-025-00819-y.

Interleukin-12 signaling drives Alzheimer's disease pathology through disrupting neuronal and oligodendrocyte homeostasis.

Schneeberger S, Kim S, Geesdorf M, Friebel E, Eede P, Jendrach M Nat Aging. 2025; .

PMID: 40082619 DOI: 10.1038/s43587-025-00816-2.

Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries.

Xu X, Kwon J, Yan R, Apio C, Song S, Heo G JAMA Netw Open. 2025; 8(3):e250562.

PMID: 40067298 PMC: 11897841. DOI: 10.1001/jamanetworkopen.2025.0562.

Applying machine learning to high-dimensional proteomics datasets for the identification of Alzheimer's disease biomarkers.

Ivarsson Orrelid C, Rosberg O, Weiner S, Johansson F, Gobom J, Zetterberg H Fluids Barriers CNS. 2025; 22(1):23.

PMID: 40033432 PMC: 11874791. DOI: 10.1186/s12987-025-00634-z.

Development of Neurodegenerative Disease Diagnosis and Monitoring from Traditional to Digital Biomarkers.

Song J, Cho E, Lee H, Lee S, Kim S, Kim J Biosensors (Basel). 2025; 15(2).

PMID: 39997004 PMC: 11852611. DOI: 10.3390/bios15020102.

References

Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R . Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2007; 30(5):682-90. PMC: 2774781. DOI: 10.1016/j.neurobiolaging.2007.08.010. View

Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N . Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64(9):1553-62. DOI: 10.1212/01.WNL.0000159740.16984.3C. View

Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

Sankaranarayanan S, Holahan M, Colussi D, Crouthamel M, Devanarayan V, Ellis J . First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2008; 328(1):131-40. DOI: 10.1124/jpet.108.143628. View

Visser P, Verhey F, Knol D, Scheltens P, Wahlund L, Freund-Levi Y . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8(7):619-27. DOI: 10.1016/S1474-4422(09)70139-5. View

Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A . Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006; 44(12):1472-80. DOI: 10.1515/CCLM.2006.258. View

Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A . Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009; 70(6):922-31. View

Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H . Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease. Am J Psychiatry. 2002; 159(3):474-6. DOI: 10.1176/appi.ajp.159.3.474. View

Blennow K, Wallin A, Fredman P, Gottfries C, Karlsson I, Svennerholm L . Intrathecal synthesis of immunoglobulins in patients with Alzheimer's disease. Eur Neuropsychopharmacol. 1990; 1(1):79-81. DOI: 10.1016/0924-977x(90)90017-5. View

10.

Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J . Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 1997; 225(3):210-2. DOI: 10.1016/s0304-3940(97)00215-2. View

11.

Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers H . Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006; 129(Pt 11):3042-50. DOI: 10.1093/brain/awl279. View

12.

Selkoe D, Wolfe M . Presenilin: running with scissors in the membrane. Cell. 2007; 131(2):215-21. DOI: 10.1016/j.cell.2007.10.012. View

13.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

14.

Siemers E . How can we recognize "disease modification" effects?. J Nutr Health Aging. 2009; 13(4):341-3. DOI: 10.1007/s12603-009-0036-7. View

15.

Price J, Morris J . Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999; 45(3):358-68. DOI: 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x. View

16.

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

17.

Agren-Wilsson A, Lekman A, Sjoberg W, Rosengren L, Blennow K, Bergenheim A . CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand. 2007; 116(5):333-9. DOI: 10.1111/j.1600-0404.2007.00890.x. View

18.

Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K . Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007; 64(6):718-26. DOI: 10.1001/archpsyc.64.6.718. View

19.

Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K . Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007; 13(11):1359-62. DOI: 10.1038/nm1653. View

20.

Clark C, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D . Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol. 2003; 60(12):1696-702. DOI: 10.1001/archneur.60.12.1696. View